Previous 10 | Next 10 |
Biohaven Pharmaceuticals (NYSE:BHVN) is scheduled to announce Q4 earnings results on Friday, February 25th, before market open. The consensus EPS Estimate is -$1.93 (+28.3% Y/Y) and the consensus Revenue Estimate is $176.93M (+403.9% Y/Y). Over the last 2 years, BHVN has beaten EPS estimates ...
AES,OTCPK:ARNGF,OTCQX:BASFY,BHVN,CGAU,CIO,CLMT,CM,CM,CNK,CRI,DSX,DTM,EOG,EOSE,EVRG,FL,FWONA,GTN,GVA,OTCPK:ICAGY,IEP,IMGN,LAMR,LI,LSXMK,MGI,NAT,NOG,OTCPK:NTIOF,NWN,OCGN,OCN,PNW,PSO,QRTEA,SII,SLCA,SMLP,SRE,SSP,STRA,STWD,TREE,UNIT,VST,ZOM For Seeking Alpha's full earnings season calendar, c...
AES,OTCPK:ARNGF,OTCQX:BASFY,BHVN,CGAU,CIO,CLMT,CM,CM,CNK,CRI,DSX,DTM,EOSE,EVRG,FL,FWONA,GTN,GVA,OTCPK:ICAGY,IEP,IMGN,LAMR,LI,LSXMK,NOG,OTCPK:NTIOF,NWN,OCGN,OCN,PNW,PSO,QRTEA,SLCA,SMLP,SRE,SSP,STRA,STWD,TREE,UNIT,VST For Seeking Alpha's full earnings season calendar, click here. For fur...
Biohaven Pharmaceutical (NYSE:BHVN) began enrollment in a phase 2/3 trial of Nurtec ODT (rimegepant) 75 mg in patients with chronic rhinosinusitis (CRS) with or without nasal polyps. Nurtec ODT is currently approved for the acute and preventive treatment of migraine. The trial will enroll ~20...
Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT PR Newswire NEW HAVEN, Conn. , Feb. 22, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfo...
BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022 PR Newswire NEW HAVEN, Conn. , Feb. 16, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-...
The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the technology sector to underperform value and biotech. After the sell-off, biotech companies' valuation is close to the 2018 level even tho...
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea - Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial...
Hardware LDN Debuts Fall/Winter 2022 Collection PR Newswire NEW YORK , Feb.12, 2022 /PRNewswire/ -- Heating up the runway this winter, Jessica Horwell makes a return to New York Fashion Week, captivating the city with her signature execution of sexy elegance...
NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports - Long-term acute treatment of migraine attacks with rimegepant 75 mg lowered monthly disease burden by reducing ...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-07-24 06:30:09 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for BHVN on July 24, 2024 04:48AM ET. BHVN was trading at $37.81 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy reco...
2024-07-24 06:00:03 ET Terence Flynn from Morgan Stanley issued a price target of $58.00 for BHVN on 2024-07-24 04:48:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $37.81. The overall price target consensus is at $4...
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...